# Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM

> **NCT02467920** · PHASE4 · COMPLETED · sponsor: **Huazhong University of Science and Technology** · enrollment: 349 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** glargine + exenatide
- **DRUG:** aspart 30

## Key facts

- **NCT ID:** NCT02467920
- **Lead sponsor:** Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 349 (ACTUAL)
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02467920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02467920, "Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02467920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*